ScientiaCME Prediction and management of bone complications in prostate cancer
Each year, over 268,000 cases of prostate cancer are diagnosed. Although early prostate cancer may be cured with surgery or radiation therapy, more than 50% of men will experience recurrence after definitive treatment. New treatment options for advanced prostate cancer have further improved survival and increased the number of patients living with castration-resistant prostate cancer (CRPC). But despite the established improvements in survival, a cornerstone of treatment, androgen deprivation therapy (ADT), has been associated with well-characterized negative effects on bone health like skeletal-related events (SREs) and bone metastases. These complications the primary drivers of morbidity and mortality among people with CRPC. Maintaining bone health in patients with CRPC requires routine monitoring and proactive management. Bone mineral density (BMD) loss places men with CRPC at elevated risk for osteoporosis and future fractures.
Cost: Free
View Offer chevron_rightDetails
Each year, over 268,000 cases of prostate cancer are diagnosed. Although early prostate cancer may be cured with surgery or radiation therapy, more than 50% of men will experience recurrence after definitive treatment. New treatment options for advanced prostate cancer have further improved survival and increased the number of patients living with castration-resistant prostate cancer (CRPC). But despite the established improvements in survival, a cornerstone of treatment, androgen deprivation therapy (ADT), has been associated with well-characterized negative effects on bone health like skeletal-related events (SREs) and bone metastases. These complications the primary drivers of morbidity and mortality among people with CRPC. Maintaining bone health in patients with CRPC requires routine monitoring and proactive management. Bone mineral density (BMD) loss places men with CRPC at elevated risk for osteoporosis and future fractures.
Learning Objectives
By the end of the session the participant will be able to:
- Identify patients with prostate cancer who are at risk for SREs.
- Review the role of conventional and next-generation imaging for the identification of SREs and bone metastases in patients with prostate cancer.
- Recall when to initiate bone-targeted pharmacotherapy in patients with prostate cancer.
- Compare the safety and efficacy of medications to prevent SREs and treat symptomatic bone metastases in patients with prostate cancer.
- Formulate a plan to delay or prevent the development of SREs or treat symptomatic bone metastases in patients with prostate cancer.
Target Audience
The following healthcare professionals: Urologists, medical and radiation oncologists, primary care physicians, nuclear medicine specialists, radiologists, and endocrinologists; physician assistants, nurse practitioners, and pharmacists who treat prostate cancer; and any other healthcare professionals who commonly care for patients with prostate cancer.